Psoriatic Arthritis (PsA) is an inflammatory spondyloarthritis that occurs in patients with psoriasis, a common inflammatory skin disease. A large proportion of patients with PsA develop progressive joint damage that leads to disability and poor quality of life. Early risk stratification of patients who are likely to develop joint damage will be a step towards precision medicine and help tailor therapy. Biomarkers may prove useful in risk stratification. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has recognized that identifying such prognostic biomarkers is an important research endeavour.